These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 38652202)
1. Developing a Novel Enzalutamide-Resistant Prostate Cancer Model via AR F877L Mutation in LNCaP Cells. Wang R; Ma S; Xu N; Gan Y; Li P; Zhang J; Zhang Z; Gu Q; Xiang J Curr Protoc; 2024 Apr; 4(4):e1033. PubMed ID: 38652202 [TBL] [Abstract][Full Text] [Related]
2. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Coleman DJ; Van Hook K; King CJ; Schwartzman J; Lisac R; Urrutia J; Sehrawat A; Woodward J; Wang NJ; Gulati R; Thomas GV; Beer TM; Gleave M; Korkola JE; Gao L; Heiser LM; Alumkal JJ Oncotarget; 2016 Jun; 7(26):40690-40703. PubMed ID: 27276681 [TBL] [Abstract][Full Text] [Related]
3. TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer. Yoshida S; Kajiwara D; Seki M; Tayama M; Tanaka Y; Mizutani H; Fujita R; Yamamura K; Okajima S; Asai M; Minamiguchi K Mol Oncol; 2024 Aug; 18(8):1980-2000. PubMed ID: 38600681 [TBL] [Abstract][Full Text] [Related]
4. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201). Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578 [TBL] [Abstract][Full Text] [Related]
5. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. Kregel S; Chen JL; Tom W; Krishnan V; Kach J; Brechka H; Fessenden TB; Isikbay M; Paner GP; Szmulewitz RZ; Vander Griend DJ Oncotarget; 2016 May; 7(18):26259-74. PubMed ID: 27036029 [TBL] [Abstract][Full Text] [Related]
6. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322 [TBL] [Abstract][Full Text] [Related]
7. Structural and molecular insights into the mechanism of resistance to enzalutamide by the clinical mutants in androgen receptor (AR) in castration-resistant prostate cancer (CRPC) patients. Khan A; Mao Y; Tahreem S; Wei DQ; Wang Y Int J Biol Macromol; 2022 Oct; 218():856-865. PubMed ID: 35905763 [TBL] [Abstract][Full Text] [Related]
8. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment. Kregel S; Wang C; Han X; Xiao L; Fernandez-Salas E; Bawa P; McCollum BL; Wilder-Romans K; Apel IJ; Cao X; Speers C; Wang S; Chinnaiyan AM Neoplasia; 2020 Feb; 22(2):111-119. PubMed ID: 31931431 [TBL] [Abstract][Full Text] [Related]
9. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960 [TBL] [Abstract][Full Text] [Related]
10. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. Graham L; Schweizer MT Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852 [TBL] [Abstract][Full Text] [Related]
11. Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Li Q; Deng Q; Chao HP; Liu X; Lu Y; Lin K; Liu B; Tang GW; Zhang D; Tracz A; Jeter C; Rycaj K; Calhoun-Davis T; Huang J; Rubin MA; Beltran H; Shen J; Chatta G; Puzanov I; Mohler JL; Wang J; Zhao R; Kirk J; Chen X; Tang DG Nat Commun; 2018 Sep; 9(1):3600. PubMed ID: 30190514 [TBL] [Abstract][Full Text] [Related]
12. The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide. Prekovic S; van Royen ME; Voet AR; Geverts B; Houtman R; Melchers D; Zhang KY; Van den Broeck T; Smeets E; Spans L; Houtsmuller AB; Joniau S; Claessens F; Helsen C Mol Cancer Ther; 2016 Jul; 15(7):1702-12. PubMed ID: 27196756 [TBL] [Abstract][Full Text] [Related]
13. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones. Leung JK; Tam T; Wang J; Sadar MD Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481 [TBL] [Abstract][Full Text] [Related]
14. Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide. Hong Z; Xiang Z; Zhang P; Wu Q; Xu C; Wang X; Shi G; Hong Z; Wu D Clin Transl Med; 2021 Jul; 11(7):e495. PubMed ID: 34323404 [TBL] [Abstract][Full Text] [Related]
15. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells. Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525 [TBL] [Abstract][Full Text] [Related]
16. CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer. Chen X; Wu Y; Wang X; Xu C; Wang L; Jian J; Wu D; Wu G Eur J Med Res; 2022 Jul; 27(1):105. PubMed ID: 35780240 [TBL] [Abstract][Full Text] [Related]
17. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor. Patki M; Huang Y; Ratnam M Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779 [TBL] [Abstract][Full Text] [Related]
18. Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide. Hoefer J; Akbor M; Handle F; Ofer P; Puhr M; Parson W; Culig Z; Klocker H; Heidegger I Oncotarget; 2016 Sep; 7(37):59781-59794. PubMed ID: 27486973 [TBL] [Abstract][Full Text] [Related]
19. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth. Yamamoto Y; Loriot Y; Beraldi E; Zhang F; Wyatt AW; Al Nakouzi N; Mo F; Zhou T; Kim Y; Monia BP; MacLeod AR; Fazli L; Wang Y; Collins CC; Zoubeidi A; Gleave M Clin Cancer Res; 2015 Apr; 21(7):1675-87. PubMed ID: 25634993 [TBL] [Abstract][Full Text] [Related]
20. Loss of Long Noncoding RNA Ghildiyal R; Sawant M; Renganathan A; Mahajan K; Kim EH; Luo J; Dang HX; Maher CA; Feng FY; Mahajan NP Cancer Res; 2022 Jan; 82(1):155-168. PubMed ID: 34740892 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]